Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and NK Cell Infusion in Malignant Tumors
NCT05143125Phase 2Unknown
- Sponsor
- Shenzhen University General Hospital
- Start
- Feb 2021
- Primary completion
- Feb 2024
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous activated and expanded natural killer cells and decitabine in cancer, sponsored by Shenzhen University General Hospital. Primary endpoint: Disease-free survival at 2 years. Status: unknown.
02
Drugs
autologous activated and expanded natural killer cellsdecitabine
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05143125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05143125.